agilon health (AGL) Q2 2026 earnings review
A Remarkable One-Year Turnaround
Exactly one year after a disastrous Q2 2025 where agilon withdrew guidance and replaced its CEO, the company has delivered a powerful beat-and-raise quarter. The strategy of pruning unprofitable members and renegotiating payer contracts is working: despite a 10% YoY drop in total membership, revenue grew 7%. Profitability is reversing from steep losses to strong gains, with Adjusted EBITDA swinging from negative $83M a year ago to positive $70M. Management's confidence is reflected in a massive upward revision to full-year guidance, raising the Adjusted EBITDA midpoint from $25M to $85M.
🐂 Bull Case
The company shed over 60,000 members YoY, yet revenue accelerated to 7% growth. This proves the economic model works when disciplined contracting replaces growth-at-all-costs.
The enhanced data pipeline implemented over the last 12 months is actively repairing the risk adjustment failures of 2025. Better Burden of Illness (BOI) execution directly drove the $197M medical margin.
🐻 Bear Case
Q2 results were heavily padded by favorable prior-period claims development. Q3 guidance implies Adjusted EBITDA will decelerate sharply to roughly breakeven ($0 midpoint).
Medicare Advantage lives dropped 12% YoY. While necessary for short-term survival, agilon must eventually prove it can grow organically in a punishing Medicare rate environment.
⚖️ Verdict: 🟢
Bullish. Management promised 2026 would be a bridge year to profitability, and they are over-delivering. Exiting unprofitable contracts was a painful but necessary surgery that has fundamentally stabilized the balance sheet.
Key Themes
Payer Recontracting & Member Pruning
The decision to aggressively prune unprofitable contracts and exit bad markets is yielding dramatic results. Total members live on platform contracted 10% YoY (614k to 549k), but total revenues shifted from a 7% YoY decline in Q1 to a 7% YoY increase in Q2. This represents a reversing trend in revenue quality, showcasing immense per-member pricing power as the company secures a higher percentage of premiums.
Enhanced Data Pipeline & BOI Execution
The catastrophic risk adjustment shortfalls of 2025 appear completely resolved. Management's investment in an enhanced data pipeline and AI-driven suspecting algorithms for Burden of Illness (BOI) capture is flowing straight to the bottom line. This infrastructure upgrade was the primary catalyst for raising full-year revenue and margin guidance.
Favorable Medical Cost Trends
Medical services expense is decelerating significantly. In Q2 2025, it cost $1.44B to generate $1.39B in revenue. In Q2 2026, medical expenses dropped to $1.29B while revenue rose to $1.49B. Management noted 'favorable medical cost trends' and estimates core trends will remain in the low 7% range, allowing operating leverage to finally materialize.
Sustainability of Q2 Profitability Peak
While the $197M Medical Margin is a massive headline win, the narrative of a permanent new baseline is contradicted by the Q3 guidance. The Q2 print was boosted by 'favorable first quarter 2026 and prior year claims development.' Consequently, Q3 Medical Margin guidance drops sequentially to $110M (midpoint), and Q3 Adjusted EBITDA is guided to $0 (midpoint), meaning Q2 was an anomaly, not the new run-rate.
Medicare Advantage Footprint Contraction
Core Medicare Advantage (MA) membership is decelerating, down 12% YoY (from 498k to 437k). ACO members also declined 3% YoY to 112k. While shedding unprofitable lives was a core tenet of the turnaround strategy, the continued shrinkage of the primary volume engine raises questions about long-term top-line sustainability once the pruning phase is complete.
Macro Rate Headwinds Persist
Though agilon is navigating 2026 masterfully, the broader Medicare Advantage macro picture remains hostile. Prior call transcripts highlighted the 2027 CMS advance rate notice as a major hurdle. agilon's success relies heavily on generating clinical savings to offset these ongoing benchmark rate pressures.
Other KPIs
Reversing. A massive swing from a $52 million Gross Loss in the same quarter last year. This highlights the fundamental repair of unit economics at the patient level.
Stable. The company reported $257 million in cash, cash equivalents, and marketable securities, plus an additional $83 million associated with unconsolidated ACO entities. With Adjusted EBITDA turning highly positive, near-term liquidity fears that plagued the stock in 2025 have been entirely neutralized.
Guidance
Accelerating. Management raised both the floor and ceiling from the prior range of $5.680B-$5.805B, reflecting stronger BOI execution and pricing power.
Accelerating dramatically. Raised from a prior midpoint of $25M to $85M. This signals that the structural improvements in medical margins and corporate cost-cutting are proving far more durable than management conservatively estimated in Q1.
Accelerating. Raised significantly from the previous $350M-$400M range, absorbing the favorable claims development seen in the first half of the year.
Decelerating sequentially. Dropping from $70M in Q2 to a midpoint of breakeven in Q3. This highlights that Q2 was heavily influenced by favorable retro-adjustments, and underlying Q3 run-rate profitability remains tight.
Key Questions
Quantifying Prior-Period Development
The Q2 Medical Margin of $197M was aided by favorable Q1 and prior-year claims development. Can you quantify the exact dollar amount of these retro-adjustments to help us model the true structural run-rate?
Pivoting Back to Growth
With Medicare Advantage membership down 12% YoY, you have successfully pruned the unprofitable tail. When do you anticipate returning to net organic membership growth, and what will customer acquisition cost look like in this tighter rate environment?
2027 Contract Visibility
Given the ongoing pressures from the CMS rate notices, what early visibility do you have into 2027 payer contract negotiations, and are payers continuing to accept your demands for higher premium share?